EGFR/B7H3-ADC (NeoMab)

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameEGFR/B7H3-ADC (NeoMab)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-CD276Anti-Epidermal growth factor receptor erbB1DNA topoisomerase I inhibitors
TargetsCD276 antigenEpidermal growth factor receptor erbB1DNA topoisomerase I
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGem Pharmatech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGem Pharmatech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A